Skip navigation

Choose Change

IT WAS WITH a growing sense of apprehension that I read the letter sent in June from the U.S. Senate finance committee to pharmaceutical companies asking them to explain their process for awarding educational grants. The senators want to make sure that grants to healthcare organizations are not a guise for promotion and influence-peddling. They said they were gathering information to see if further guidance or legislation (gulp) is needed. (See news story, page 15.)

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.